Maryam Mooghali

Economics, Econometrics and FinanceMedicinePharmacology, Toxicology and Pharmaceutics

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Use of Expedited Regulatory Programs and Clinical Development Times for FDA-Approved Novel Therapeutics”.

Use of Expedited Regulatory Programs and Clinical Development Times for FDA-Approved Novel Therapeutics

JAMA Network Open(2023)10.1001/jamanetworkopen.2023.31753

N/A

0DataRank · unranked

12 citations

Maryam Mooghali, Reshma Ramachandran, Joseph S. Ross, Joshua D. Wallach, Alissa K. Wong

Nonconcurrent Control Use in FDA Approval of High-Risk Medical Devices

JAMA Network Open(2025)10.1001/jamanetworkopen.2025.6230

N/A

0DataRank · unranked

4 citations

Sanket S. Dhruva, Hollin R.L. Hakimian, Vinay K Rathi, Kushal T. Kadakia, Joseph S. Ross +1 more